LUXTURNA Continues to Lead in Retinal Gene Therapy with Increased Market Penetration ...
DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...
Would Jalen Milroe be a good fit for the Pittsburgh Steelers? | The Herd
Colin Cowherd and Albert Breer discuss Mike Tomlin and Jalen Milroe meeting up, and if the Pittburgh Steelers would be a good ...
MeiraGTx Holdings: Gaining Regulatory Focus
MeiraGTx's innovative gene therapies for ocular diseases & more are backed by strong clinical data and funding. Click here to find out why MGTX stock is a Buy.
pharmaphorum6 天
Beacon lights up with $170m for retinal disease gene therapy
XLRP is predominantly caused by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene, and AGTC-501 is designed to deliver a full-length replacement for the RPGR protein. Other gene ...
pharmaphorum2 天
Nanoscope gene therapy clears ph2 retinitis pigmentosa trial
Other gene therapies for RP - from companies including Biogen, Syncona, SparingVision ,and ProQR Therapeutics - are targeting specific mutations in the RPGR, USH2A, and RHO genes, for example.
DelveInsight Business Research, LLP: LUXTURNA Continues to Lead in Retinal Gene Therapy ...
LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...